Literature DB >> 25048189

Pancreatic neuroendocrine tumours: correlation between MSCT features and pathological classification.

Yanji Luo1, Zhi Dong, Jie Chen, Tao Chan, Yuan Lin, Minhu Chen, Zi-Ping Li, Shi-Ting Feng.   

Abstract

OBJECTIVES: We aimed to evaluate the multi-slice computed tomography (MSCT) features of pancreatic neuroendocrine neoplasms (P-NENs) and analyse the correlation between the MSCT features and pathological classification of P-NENs.
METHODS: Forty-one patients, preoperatively investigated by MSCT and subsequently operated on with a histological diagnosis of P-NENs, were included. Various MSCT features of the primary tumour, lymph node, and distant metastasis were analysed. The relationship between MSCT features and pathologic classification of P-NENs was analysed with univariate and multivariate models.
RESULTS: Contrast-enhanced images showed significant differences among the three grades of tumours in the absolute enhancement (P = 0.013) and relative enhancement (P = 0.025) at the arterial phase. Univariate analysis revealed statistically significant differences among the tumours of different grades (based on World Health Organization [WHO] 2010 classification) in tumour size (P = 0.001), tumour contour (P < 0.001), cystic necrosis (P = 0.001), tumour boundary (P = 0.003), dilatation of the main pancreatic duct (P = 0.001), peripancreatic tissue or vascular invasion (P < 0.001), lymphadenopathy (P = 0.011), and distant metastasis (P = 0.012). Multivariate analysis suggested that only peripancreatic tissue or vascular invasion (HR 3.934, 95 % CI, 0.426-7.442, P = 0.028) was significantly associated with WHO 2010 pathological classification.
CONCLUSIONS: MSCT is helpful in evaluating the pathological classification of P-NENs. KEY POINTS: • P-NENs are potentially malignant, and classification of P-NENs carries important prognostic value. • MSCT plays an important role in the diagnosis and staging of P-NENs. • Correlations between classification of P-NENs and imaging findings have not been systematically evaluated. • MSCT could predict P-NENs classification and may be a useful prognostication tool.

Entities:  

Mesh:

Year:  2014        PMID: 25048189     DOI: 10.1007/s00330-014-3317-4

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  19 in total

1.  Value of both WHO and TNM classification systems for patients with pancreatic endocrine tumors: results of a single-center series.

Authors:  Riccardo Casadei; Claudio Ricci; Raffaele Pezzilli; Davide Campana; Paola Tomassetti; Lucia Calculli; Donatella Santini; Nicola Antonacci; Francesco Minni
Journal:  World J Surg       Date:  2009-11       Impact factor: 3.352

2.  Preoperative assessment of nonfunctioning pancreatic endocrine tumours: role of MDCT and MRI.

Authors:  Giovanni Foti; Letizia Boninsegna; Massimo Falconi; Roberto Pozzi Mucelli
Journal:  Radiol Med       Date:  2013-07-25       Impact factor: 3.469

3.  Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression.

Authors:  Francesco Panzuto; Letizia Boninsegna; Nicola Fazio; Davide Campana; Maria Pia Brizzi; Gabriele Capurso; Aldo Scarpa; Filippo De Braud; Luigi Dogliotti; Paola Tomassetti; Gianfranco Delle Fave; Massimo Falconi
Journal:  J Clin Oncol       Date:  2011-05-09       Impact factor: 44.544

Review 4.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors:  James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

5.  Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours.

Authors:  R Bettini; L Boninsegna; W Mantovani; P Capelli; C Bassi; P Pederzoli; G F Delle Fave; F Panzuto; A Scarpa; M Falconi
Journal:  Ann Oncol       Date:  2008-01-21       Impact factor: 32.976

6.  Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution.

Authors:  Sara Ekeblad; Britt Skogseid; Kristina Dunder; Kjell Oberg; Barbro Eriksson
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

7.  Pancreatic endocrine tumors: tumor blood flow assessed with perfusion CT reflects angiogenesis and correlates with prognostic factors.

Authors:  Gaspard d'Assignies; Anne Couvelard; Stéphane Bahrami; Marie-Pierre Vullierme; Pascal Hammel; Olivia Hentic; Alain Sauvanet; Pierre Bedossa; Philippe Ruszniewski; Valérie Vilgrain
Journal:  Radiology       Date:  2008-12-18       Impact factor: 11.105

8.  Incidental neuroendocrine tumors of the pancreas: MDCT findings and features of malignancy.

Authors:  Anna Gallotti; Rocio Perez Johnston; Pietro A Bonaffini; Thun Ingkakul; Vikram Deshpande; Carlos Fernández-del Castillo; Dushyant V Sahani
Journal:  AJR Am J Roentgenol       Date:  2013-02       Impact factor: 3.959

9.  Islet cell tumors of the pancreas: pathologic-imaging correlation among size, necrosis and cysts, calcification, malignant behavior, and functional status.

Authors:  P C Buetow; T V Parrino; J L Buck; L Pantongrag-Brown; P R Ros; A H Dachman; D F Cruess
Journal:  AJR Am J Roentgenol       Date:  1995-11       Impact factor: 3.959

10.  Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression.

Authors:  A Couvelard; D O'Toole; H Turley; R Leek; A Sauvanet; C Degott; P Ruszniewski; J Belghiti; A L Harris; K Gatter; F Pezzella
Journal:  Br J Cancer       Date:  2005-01-17       Impact factor: 7.640

View more
  12 in total

1.  Is the combination of MR and CT findings useful in determining the tumor grade of pancreatic neuroendocrine tumors?

Authors:  Fumihito Toshima; Dai Inoue; Takahiro Komori; Kotaro Yoshida; Norihide Yoneda; Tetsuya Minami; Osamu Matsui; Hiroko Ikeda; Toshifumi Gabata
Journal:  Jpn J Radiol       Date:  2017-03-03       Impact factor: 2.374

2.  Contrast-enhanced MDCT in patients with pancreatic neuroendocrine tumours: correlation with histological findings and diagnostic performance in differentiation between tumour grades.

Authors:  E Belousova; G Karmazanovsky; A Kriger; D Kalinin; L Mannelli; A Glotov; N Karelskaya; O Paklina; A Kaldarov
Journal:  Clin Radiol       Date:  2016-11-24       Impact factor: 2.350

Review 3.  State-of-the-art Imaging of Pancreatic Neuroendocrine Tumors.

Authors:  Eric P Tamm; Priya Bhosale; Jeffrey H Lee; Eric M Rohren
Journal:  Surg Oncol Clin N Am       Date:  2016-04       Impact factor: 3.495

4.  Can MDCT or EUS features predict the histopathological grading scheme of pancreatic neuroendocrine neoplasms?

Authors:  Hui Zhu; Lang Ying; Wei Tang; Xiujiang Yang; Bo Sun
Journal:  Radiol Med       Date:  2017-02-07       Impact factor: 3.469

5.  Differential diagnosis of pancreatic cancer from other solid tumours arising from the periampullary area on MDCT.

Authors:  Suk Ki Jang; Jung Hoon Kim; Ijin Joo; Ju Hyun Jeon; Kyung Sook Shin; Joon Koo Han; Byung Ihn Choi
Journal:  Eur Radiol       Date:  2015-04-28       Impact factor: 5.315

6.  Prognostic value of CT findings to predict survival outcomes in patients with pancreatic neuroendocrine neoplasms: a single institutional study of 161 patients.

Authors:  Dong Wook Kim; Hyoung Jung Kim; Kyung Won Kim; Jae Ho Byun; So Yeon Kim; Ki Byung Song; Nikhil H Ramaiya; Sree Harsha Tirumani; Seung-Mo Hong
Journal:  Eur Radiol       Date:  2015-08-08       Impact factor: 5.315

7.  Isoattenuating insulinomas at biphasic contrast-enhanced CT: frequency, clinicopathologic features and perfusion characteristics.

Authors:  Liang Zhu; Hua-Dan Xue; Hao Sun; Xuan Wang; Yong-Lan He; Zheng-Yu Jin; Yu-Pei Zhao
Journal:  Eur Radiol       Date:  2016-01-26       Impact factor: 5.315

8.  Dynamic enhanced CT: is there a difference between liver metastases of gastroenteropancreatic neuroendocrine tumor and adenocarcinoma.

Authors:  Yong Cui; Zhong-Wu Li; Xiao-Ting Li; Shun-Yu Gao; Ying Li; Jie Li; Hui-Ci Zhu; Lei Tang; Kun Cao; Ying-Shi Sun
Journal:  Oncotarget       Date:  2017-11-20

9.  Utility of CT in differentiating liver metastases of well-differentiated gastroenteropancreatic neuroendocrine neoplasms from poorly-differentiated neuroendocrine neoplasms.

Authors:  Yong Cui; Xiaoting Li; Shunyu Gao; Zhongwu Li; Yanling Li; Ming Lu; Yingshi Sun
Journal:  Chin J Cancer Res       Date:  2018-02       Impact factor: 5.087

10.  A small pancreatic hamartoma with an obstruction of the main pancreatic duct and avid FDG uptake mimicking a malignant pancreatic tumor: a systematic case review.

Authors:  Hiroaki Nagano; Masayuki Nakajo; Yoshihiko Fukukura; Yoriko Kajiya; Atsushi Tani; Sadao Tanaka; Mari Toyota; Toru Niihara; Masaki Kitazono; Toyokuni Suenaga; Takashi Yoshiura
Journal:  BMC Gastroenterol       Date:  2017-12-06       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.